Niccolò Buetti1,2, Mohamed Abbas1, Didier Pittet1, Marlieke E A de Kraker1, Daniel Teixeira1, Marie-Noëlle Chraiti1, Valérie Sauvan1, Julien Sauser1, Stephan Harbarth1, Walter Zingg1,3. 1. Infection Control Program and World Health Organization Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland. 2. Unité Mixte de Recherche ( UMR ) 1137 , Infection, Antimicrobials, Modelling, Evolution (IAME), INSERM, Université de Paris, Paris, France. 3. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
Abstract
Importance: Peripheral intravenous catheters (PVCs) are the most frequently used indwelling devices in hospitals worldwide. Peripheral intravenous catheter bloodstream infections (PVC-BSIs) are rare, but severe and preventable, adverse events. Objective: To investigate the incidence of PVC-BSIs after changing the policy of routine PVC replacement every 96 hours to clinically indicated replacement. Design, Setting, and Participants: This institution-wide, observational cohort study evaluated all patients hospitalized at a large university-affiliated hospital with 10 sites in Western Switzerland with a PVC insertion between January 1, 2016, and February 29, 2020. Exposures: Peripheral intravenous catheters were routinely replaced every 96 hours until March 31, 2018 (baseline period). Between April 1, 2018, and October 15, 2019, PVCs were replaced if clinically indicated (intervention period). From October 16, 2019, PVCs were again routinely replaced every 96 hours (reversion period). Main Outcomes and Measures: The PVC-BSI rates and PVC-BSI incidence rate ratios (IRRs) during each period. Results: A total of 412 631 PVCs with documented catheter duration were included (164 331 patients; median [interquartile range] patient age, 51 [33-72] years; 88 928 [54.1%] female): 241 432 PVCs at baseline, 130 779 at intervention, and 40 420 at reversion. Eleven PVC-BSIs were observed during the baseline period, 46 during the intervention, and 4 during the reversion period. Although the monthly number of PVC-days remained stable during all study periods, the number of monthly inserted PVCs decreased during the intervention period. The number of PVCs still in place more than 4 or more than 7 days was higher during the intervention period compared with the baseline and reversion periods. A significantly increased IRR of PVC-BSIs was observed for the intervention period (IRR, 7.20; 95% CI, 3.65-14.22; P < .001) compared with baseline, whereas during the reversion period there was no significant increase (IRR, 1.35; 95% CI, 0.30 6.17; P = .69). Conclusions and Relevance: The results of this cohort study using a large, prospective surveillance database suggest that replacement of PVCs only when clinically indicated may be associated with an increased risk of PVC-BSI compared with routine replacement. Even if PVC-associated BSI is a rare event, the use of PVCs in most patients makes this outcome relevant.
Importance: Peripheral intravenous catheters (PVCs) are the most frequently used indwelling devices in hospitals worldwide. Peripheral intravenous catheter bloodstream infections (PVC-BSIs) are rare, but severe and preventable, adverse events. Objective: To investigate the incidence of PVC-BSIs after changing the policy of routine PVC replacement every 96 hours to clinically indicated replacement. Design, Setting, and Participants: This institution-wide, observational cohort study evaluated all patients hospitalized at a large university-affiliated hospital with 10 sites in Western Switzerland with a PVC insertion between January 1, 2016, and February 29, 2020. Exposures: Peripheral intravenous catheters were routinely replaced every 96 hours until March 31, 2018 (baseline period). Between April 1, 2018, and October 15, 2019, PVCs were replaced if clinically indicated (intervention period). From October 16, 2019, PVCs were again routinely replaced every 96 hours (reversion period). Main Outcomes and Measures: The PVC-BSI rates and PVC-BSI incidence rate ratios (IRRs) during each period. Results: A total of 412 631 PVCs with documented catheter duration were included (164 331 patients; median [interquartile range] patient age, 51 [33-72] years; 88 928 [54.1%] female): 241 432 PVCs at baseline, 130 779 at intervention, and 40 420 at reversion. Eleven PVC-BSIs were observed during the baseline period, 46 during the intervention, and 4 during the reversion period. Although the monthly number of PVC-days remained stable during all study periods, the number of monthly inserted PVCs decreased during the intervention period. The number of PVCs still in place more than 4 or more than 7 days was higher during the intervention period compared with the baseline and reversion periods. A significantly increased IRR of PVC-BSIs was observed for the intervention period (IRR, 7.20; 95% CI, 3.65-14.22; P < .001) compared with baseline, whereas during the reversion period there was no significant increase (IRR, 1.35; 95% CI, 0.30 6.17; P = .69). Conclusions and Relevance: The results of this cohort study using a large, prospective surveillance database suggest that replacement of PVCs only when clinically indicated may be associated with an increased risk of PVC-BSI compared with routine replacement. Even if PVC-associated BSI is a rare event, the use of PVCs in most patients makes this outcome relevant.
Authors: Patricia Van Donk; Claire M Rickard; Matthew R McGrail; Glenn Doolan Journal: Infect Control Hosp Epidemiol Date: 2009-09 Impact factor: 3.254
Authors: Pedro M Olaechea; Mercedes Palomar; Francisco Álvarez-Lerma; Juan José Otal; Josu Insausti; M Jesús López-Pueyo Journal: Rev Esp Quimioter Date: 2013-03 Impact factor: 1.553
Authors: Claire M Rickard; Joan Webster; Marianne C Wallis; Nicole Marsh; Matthew R McGrail; Venessa French; Lynelle Foster; Peter Gallagher; John R Gowardman; Li Zhang; Alice McClymont; Michael Whitby Journal: Lancet Date: 2012-09-22 Impact factor: 79.321
Authors: M Pujol; A Hornero; M Saballs; M J Argerich; R Verdaguer; M Cisnal; C Peña; J Ariza; F Gudiol Journal: J Hosp Infect Date: 2007-08-27 Impact factor: 3.926
Authors: Niccolò Buetti; Mohamed Abbas; Didier Pittet; Marie-Noëlle Chraiti; Valérie Sauvan; Marlieke E A De Kraker; Matthieu Boisson; Daniel Teixeira; Walter Zingg; Stephan Harbarth Journal: Antimicrob Resist Infect Control Date: 2022-06-03 Impact factor: 6.454